Profusa Nears EU Regulatory Milestone with ISO 13485 Certification
Event summary
- Profusa received ISO 13485 certification from GMED, a key step toward CE marking for its Lumee® Oxygen Platform.
- The certification is expected to be finalized in early October 2026.
- The Lumee® Oxygen Platform provides continuous, real-time monitoring of tissue oxygen levels.
- Profusa is also pursuing an option to acquire G3 Vision Labs, Inc.
The big picture
Profusa's progress toward ISO 13485 certification marks a critical step in its quest to bring the Lumee® Oxygen Platform to the EU market. The platform's real-time tissue oxygen monitoring could disrupt traditional patient monitoring methods, aligning with broader trends in digital health and personalized medicine. The potential acquisition of G3 Vision Labs further positions Profusa as a player in the diagnostics space, though regulatory and integration risks remain.
What we're watching
- Regulatory Timing
- Whether Profusa can secure CE marking by early October 2026 as planned.
- Market Adoption
- The pace at which clinicians integrate continuous tissue oxygen monitoring into treatment protocols.
- Strategic Integration
- How the potential acquisition of G3 Vision Labs will impact Profusa's diagnostics capabilities.
Related topics
